- Home
- MTR vs PHGE Comparison
MTR vs PHGE Comparison
Compare MTR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTR | PHGE |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 6.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MTR | PHGE |
|---|---|---|
| Price | $4.73 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | 2.7K | ★ 124.8K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $623,288.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.29 | $2.28 |
| 52 Week High | $10.42 | $22.06 |
Technical Indicators
Market Signals| Indicator | MTR | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 48.79 |
| Support Level | $4.58 | $2.31 |
| Resistance Level | $4.80 | $2.85 |
| Average True Range (ATR) | 0.11 | 0.59 |
| MACD | 0.02 | -0.22 |
| Stochastic Oscillator | 63.91 | 35.00 |
Price Performance
Historical ComparisonAbout MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).